Acute Myeloid Leukemia (AML)

Dr. Meyers was born and raised in rural Northern California and traveled around the country during her medical training. She developed an interest in hematology and oncology during medical school, and pursued a fellowship in that field after her internal medicine residency. While at the University of Utah, she performed laboratory research on bone marrow failure syndromes, with a focus on paroxysmal nocturnal hemoglobinuria. Her research continues at OHSU, and she currently has government and private foundation support to study the genetic changes that lead to bone marrow dysfunction and

Ruben A. Mesa, MD, FACP, is the president and executive director of Atrium Health Levine Cancer and Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He also serves as vice dean for cancer programs and professor of medicine at Wake Forest University School of Medicine. In his roles, Dr. Mesa oversees all efforts related to cancer practice, research and education across the Atrium Health system. Dr. Mesa is an international expert in hematologic cancers. He has dedicated his life's work to research and drug development for myeloproliferative neoplasms (MPNs), a group of chronic

Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute. Dr. Mascarenhas is the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, under the direction of Dr. Ronald Hoffman. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs) and evolution to acute myeloid leukemia (AML), he is focused on the evaluation of rationale based

After obtaining a BA/MS as a Vagelos Scholar in Molecular Life Sciences at the University of Pennsylvania in 2003, Dr. Lee received his MD from the University of Miami in 2007. Following his internal medicine residency at the University of Alabama at Birmingham, he completed his fellowship in hematology and oncology at the New York Presbyterian Hospital/Columbia University Medical Center from 2010-2013 where he focused on epigenetics of myelodysplastic syndromes (MDS) under Drs. Azra Raza and Benjamin Tycko. In July 2013, Dr. Lee was recruited to serve in the Leukemia Program in the Division

Dr. Lane received his MD and PhD degrees from Washington University. He completed his residency in internal medicine at Brigham and Women's Hospital, and his fellowships in hematology and medical oncology at DFCI. His research focuses on developing new treatments for leukemia by studying the genetic changes that occur in cancer and how they alter the normal development of blood cells.

Dr Kogan and GW Center for Integrative Medicine have been providing integrative and complementary consultations and services for patients with Bone Marrow Disorders.

Dr. Tapan Kadia received his M.D. degree from Robert Wood Johnson Medical School in Piscataway, New Jersey. He completed his clinical internship in 2002, clinical residency in 2004, and chief residency in 2005, each at Baylor College of Medicine... Dr. Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized